Helmholtz funds cohort study

October 22, 2008

Berlin, 22 October 2008 - The Helmholtz Association will invest around €20 million over the next five years to put together a large-scale, long-term cohort study. The goal of the study will be to illuminate the causes of common health problems like cardiovascular disease, can-cer, diabetes and dementia, as well as to identify risk factors and effective methods of prevention. The Helmholtz Association's Senate reached the decision today.

The cohort study will observe a group of 200,000 people over a period of ten to twenty years. The subjects will be healthy at the time they are recruited and will have given their permission to take part in the study. They will undergo regular medical checkups and answer questions about their lifestyle habits and socioeconomic status. Over time some of them will develop medical conditions, and doctors will then be able to relate to the medical data the patients provided earlier in the study. This makes the study a unique tool to gain a better understanding of a variety of epidemiological questions.

The Helmholtz Association will plan and conduct the cohort study with help from universities and other national research institutions. The planning and coordination phase will begin in 2009 and last for approximately three years. "Chronic conditions are placing an increasing burden on health care systems and presenting new challenges for health care researchers, as well. Cohort studies such as this one are helpful for developing new strategies for early recognition and prevention, especially for conditions that have a variety of causes such as lifestyle habits, environmental factors and genetic risk factors", says Helmholtz Association President, Prof. Jürgen Mlynek.

All of the Helmholtz Association's health centres will be involved in the initiative, with the German Cancer Research Center in Heidelberg and the Helmholtz Zentrum München - German Research Center for Environmental Health acting as coordinators. Other participants will include the Max Delbrück Center in Berlin-Buch, the Helmholtz Centre for Infec-tion Research, the Helmholtz Centre for Neurodegenerative Diseases (which is currently in the process of being established), and the health research division of Forschungszentrum Jülich. The total cost of the ten-year initiative is estimated to be between €150-200 million.
-end-
The Helmholtz Association contributes to solving major challenges facing society, science and the economy with top scientific achievements in six research fields: Energy, Earth and Environment, Health, Key Technologies, Structure of Matter, Transport and Space. With 28,000 employees in 15 research centres and an annual budget of approximately 2.4 billion euros, the Helmholtz Association is Germany's largest scientific organisation. Its work follows in the tradition of the great natural scientist Hermann von Helmholtz (1821-1894). www.helmholtz.de

Communications and Media Relations

Helmholtz Association of German Research Centres
Thomas Gazlig
Dipl.-Biol./Dipl.-Journ.
Head of Communications and Media Relations
Berlin Office
Anna-Louisa-Karsch-Straße 2
10178 Berlin
Germany
Phone/Fax: +49 30 206329-57/60
presse@helmholtz.de

Cohort Study Coordinators:
Prof. Dr. Dr. H.-Erich Wichmann
Helmholtz Zentrum München
Phone: 089 3187-4066
wichmann@helmholtz-muenchen.de

Prof. Dr. Rudolf Kaaks
Deutsches Krebsforschungszentrum
Phone: 06221 422219

Helmholtz Association

Related Cardiovascular Disease Articles from Brightsurf:

Changes by income level in cardiovascular disease in US
Researchers examined changes in how common cardiovascular disease was in the highest-income earners compared with the rest of the population in the United States between 1999 and 2016.

Fighting cardiovascular disease with acne drug
Researchers from the European Molecular Biology Laboratory (EMBL) in Heidelberg and Stanford University have found the cause of dilated cardiomyopathy - a leading cause of heart failure - and identified a potential treatment for it: a drug already used to treat acne.

A talk with your GP may prevent cardiovascular disease
Having a general practitioner (GP) who is trained in motivational interviewing may reduce your risk of getting cardiovascular disease.

Dilemma of COVID-19, aging and cardiovascular disease
Whether individuals should continue to take angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the context of coronavirus disease 2019 (COVID-19) is discussed in this article.

Air pollution linked to dementia and cardiovascular disease
People continuously exposed to air pollution are at increased risk of dementia, especially if they also suffer from cardiovascular diseases, according to a study at Karolinska Institutet in Sweden published in the journal JAMA Neurology.

New insights into the effect of aging on cardiovascular disease
Aging adults are more likely to have - and die from - cardiovascular disease than their younger counterparts.

Premature death from cardiovascular disease
National data were used to examine changes from 2000 to 2015 in premature death (ages 25 to 64) from cardiovascular disease in the United States.

Ultrasound: The potential power for cardiovascular disease therapy
In the current issue of Cardiovascular Innovations and Applications volume 4, issue 2, pp.

Despite the ACA, millions of Americans with cardiovascular disease still can't get care
Cardiovascular disease (CVD) is the leading cause of death for Americans, yet millions with CVD or cardiovascular risk factors (CVRF) still can't access the care they need, even years after the implementation of the Affordable Care Act (ACA).

Excess weight and body fat cause cardiovascular disease
In the first Mendelian randomization study to look at this, researchers have found evidence that excess weight and body fat cause a range of heart and blood vessel diseases (rather than just being associated with it).

Read More: Cardiovascular Disease News and Cardiovascular Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.